In this study, we report a case of multidrug-resistant influenza A(H3N2) virus isolated from an immunosuppressed patient with prolonged viral shedding. We also describe the genetic characterization of the haemagglutinin, neuraminidase and M2 influenza genes. The virus contained the substitutions E119V in neuraminidase and V27A in M2, which produce resistance to oseltamivir and adamantanes, respectively. This is the first report of this dual mutation pattern in multidrug-resistant influenza A(H3N2) virus.
Influenza, which causes significant morbidity and mortality in immunocompromised patients, is often associated with prolonged viral shedding [1, 2] regardless of vaccination and antiviral therapy. The multidrug-resistant influenza viruses, including pandemic A(H1N1) and seasonal A(H1N1) and A(H3N2), as reported to date in treated immunocompromised patients [1, [3] [4] [5] [6] , have presented the E119V, R292K or H275Y mutations in the neuraminidase (NA) gene and the S31N mutation in the M2 gene, which confer oseltamivir and adamantane resistance, respectively. In this study, we report the prolonged shedding of influenza A(H3N2) virus with an unusual combination of mutations conferring multidrug resistance to oseltamivir and amantadine in an immunocompromised infant.
A 6-month-old male with a previous history of influenza A infection detected by immunochromatographic antigen detection in March 2005 that developed into interstitial chronic pneumonia, also presented a T-cellnegative, natural-killer-cell-negative and B-cell-positive severe combined immunodeficiency disease, which was diagnosed 1 month after initial detection. The chest X-ray showed interstitial bilateral infiltration and the antigen detection nasal swab tested positive for influenza A. The patient (weight 7 kg) received treatment with oseltamivir (12 mg twice daily) and amantadine (15 mg once daily, which was reduced to 7.5 mg once daily because of neurological toxicity). After receiving fludarabine and melphalan as conditioning therapy, he underwent allogenic non-identical peripheral blood transplantation from his mother in May 2005 (day 0). Total lymphocyte cell (TLC) count prior to transplantation was 1,340 cells/mm 3 (25%). On day 10, fever was observed and oxygen therapy was required because of respiratory insufficiency. On day 12, Grade II acute graft-versus-host disease (GVHD) that affected the skin and liver was observed, and he was treated with corticosteroids and tacrolimus. On day 19, respiratory difficulty persisted and a bronchoalveolar lavage (BAL) sample (sample A) was sent to our laboratory (National Influenza Center, Madrid, Spain) for further testing. Using previously described PCR assays for respiratory viruses [7, 8] , the tested BAL sample was positive for influenza A. On day 26 post-transplant and after 33 days of antiviral therapy, treatment was discontinued and the patient was discharged from hospital with the influenza A infection apparently resolved. On day 38, fever, rash and upper respiratory symptoms reappeared (TLC 1,577 cells/ mm 3 ; 9%). A nasal antigen detection swab showed that the influenza A infection remained unresolved. Because of the persistence of the respiratory symptoms and the prolonged shedding of influenza A, the patient was again treated with oseltamivir (12 mg once daily) and amantadine (7.5 mg once daily) for 15 days. On day 86, a All four samples (A, B, C and D) sent to our laboratory (National Influenza Center) and tested between June and November 2005 were identified as subtype H3N2 by haemagglutinin (HA) and NA PCR as described elsewhere [9] . Additional M2 segment amplification was performed using the outer primers for eight influenza A viral RNA segments [9] The sequencing of the NA gene revealed an E119V substitution (GenBank accession numbers EU652319, EU652320, EU652321 and EU652322), which was associated with resistance to oseltamivir in the four samples obtained from the reported case ( Figure 2A ). The segment encoding the M2 transmembrane domain showed the V27A mutation (GenBank accession numbers EU652323, EU652324, EU652325 and EU652326), which was related with the acquisition of resistance to adamantanes, in the same samples containing the E119V substitution ( Figure 2B ). The C50F substitution was found in M2 in the four samples. This cysteine in position 50 of wild-type influenza viruses is post-translationally modified by palmitoylation through a thioether linkage [10] . The mutated residues associated with resistance in NA and M2 did not show evidence of mixed viral populations. The amino acid changes found in the HA1 domain ( Figure 3 ) that affected epitope changes in antigenic sites were S189K/R (site B), N216D and N246S (site D; GenBank accession numbers EU982291, EU982292, EU982293 and EU982294). The N246S mutation also leads to the loss of an N-linked potential glycosylation site [11] . No mutations were found in the receptor binding sites.
Discussion
In this report, we describe the first documented case of multidrug resistance in an influenza A(H3N2) virus with the dual mutation pattern E119V in N2 and V27A in M2. Most of the reported cases of prolonged influenza A virus shedding in immunosuppressed patients describe resistance to neuraminidase inhibitors (NAI), adamantanes or both [1, 5, 12] . The E119V mutation detected in the immunocompromised infant with prolonged shedding described here confers oseltamivir resistance but does not affect susceptibility to zanamivir [13] . Most of the multidrug-resistant influenza A(H3N2) viruses that have been genetically characterized contain either the E119V or R292K mutation in the NA gene and the S31N mutation in the M2 segment [1, 5] . After amantadine treatment, the V27A substitution was the most frequent resistance mutation during 1999-2001 in H1N1 subtype strains [14] ; current data for the 2004-2005 influenza seasons indicate that 1.6% of the H3N2 subtype viruses contained this mutation [15] . The C50 position on the M2 segment is highly conserved among human H3N2 subtype viruses, but not in human H1N1 subtype viruses [16] . Interestingly, the loss of this palmitoylation site (C50F) was observed in the H3N2 subtype viruses in this reported case. Nevertheless, the post-translational modifications did not affect M2 ion channel activity [10] or viral replication [16] .
Continuous E119V virus shedding was confirmed for >5 months, both during and after the discontinuation of oseltamivir therapy. Viral shedding persisted after 89 days of cumulative oseltamivir therapy (Figure 1, sample D) . As previously described [1] , the presence of the NA mutation, even in the absence of antiviral pressure (Figure 1, samples B and C) , might indicate that the E119V mutation is stable in untreated immunocompromised patients. The S189K/R change is near the HA receptor binding site D190 and might have contributed to the persistence of the E119V variant, partially compensating for potentially reduced NA activity produced by decreased HA affinity [4] . The loss of potential N246 glycosylation in the antigenic site B of the HA might be an evolutionary adaptation by the virus in a patient with a deficient antibody response.
Despite the combination therapy applied in this patient, viral clearance was documented in two samples after 42 days of therapy interruption and appeared to have been associated with the immunological reconstitution. Oseltamivir and amantadine are not formally recommended in children <1 year old; however, severe immunosuppression is a life-threatening comorbid condition, and antiviral treatment of influenza infection would be advisable in this circumstance. At present, the US Food and Drug Administration authorizes treatment with oseltamivir for the pandemic A(H1N1) infection in children <1 year old (dosing recommendation 3 mg/kg twice daily). Currently, the use of amantadine is not recommended for children <1 year old (5 mg/kg/day twice daily in children ≥1 year old). It is possible that the prolonged subtherapeutic doses of both antivirals might have contributed to the development of resistance and the lack of viral clearance. The family of the infant did not receive antiviral treatment and, although it is possible that the patient was infected with an already amantadine-or oseltamivir-resistant virus, no isolates before initiation of drug treatment were available for analysis. In addition, patients infected with A(H3N2) viruses containing the E119V mutation should be treated with inhaled zanamivir or intravenous peramivir because this mutation retains susceptibility to both.
In conclusion, because pandemic A(H1N1) and contemporary A(H3N2) viruses are resistant to adamantanes and the wide use of NAI can lead to the emergence of resistant viruses, antiviral resistance testing (particularly NAI) is advisable in immunosuppressed and severely ill patients, particularly when positive results on culture and PCR assays suggest a persistent infection after or during the course of antiviral treatment.
